Fig. 3: SNRPD3 is required for the growth and proliferation of MYCN-amplified neuroblastoma cells.

SK-N-BE(2)-C and KELLY cells were transfected with siRNAs targeted against SNRPD3 or a control siRNA for 72 h, then subjected to (A) cell viability and (B) cell proliferation measurements. Differences in cell viability and proliferation were compared with siControl. C SK-N-BE(2)-C and KELLY cells were transfected with siRNAs targeting SNRPD3 or a control siRNA for 10 days (SK-N-BE(2)-C) or 14 days (KELLY), followed by colony formation assays. Differences in colony formation were compared to siControl and (D) the number of colonies were quantified. This is a representative image of three biologically independent experiments (n = 3), mean ± SEM, where the P value was determined through a one-way ANOVA, with Dunnett multiple comparison testing. SK-N-BE(2)-C cells expressing SNRPD3 shRNA (shSNRPD3) were xenografted into immunodeficient nude mice. Once tumours reached 4−5 mm, mice were divided into DOX (2 mg/mL doxycycline) or vehicle (water containing 5% sucrose) control (Vehicle) subgroups. E Tumour volume was measured (n = 7 mice per treatment group) from day 0 post-treatment until the tumour reached ≥1000 mm³ or a maximum holding time of 12 weeks. The effect of DOX on tumour progression was evaluated using a two-way ANOVA. F Representative photos of either vehicle- (day 17 post treatment) or DOX-treated (day 65 post treatment) mice. G Kaplan–Meier survival curves showed the probability of overall survival of the mice (n = 7 mice per treatment group). A log rank test was used to obtain p-value. All results represent n = 3 independent biological replicates, mean ± SEM, where the P value was determined through a one-way ANOVA, with Dunnett multiple comparison testing, unless stated otherwise.